Answer
Migraine with focal neurological symptoms, often called aura, is a contraindication. New or worsening migraine while using the patch needs prompt clinical review.
Sources for this answer
- EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch — Current selected SmPCemc · Summary of Product Characteristics
- NHSNHS · NHS medicine guidance
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.